Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects With Age-Related Macular Degeneration

NCT00429936 is registered in ClinicalTrials.gov with Sirion Therapeutics, Inc. as lead sponsor.

NCT NCT00429936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00429936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects With Age-Related Macular Degeneration
Lead sponsor
Sirion Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2006
Completion date
May 31, 2010
Enrollment
245 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

dry age related macular degeneration, geographic atrophy